Alteration of Gut Microbiome in Patients With Schizophrenia Indicates Links Between Bacterial Tyrosine Biosynthesis and Cognitive Dysfunction
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Alteration of Gut Microbiome in Patients With Schizophrenia Indicates Links Between Bacterial Tyrosine Biosynthesis and Cognitive Dysfunction. / Thirion, Florence; Speyer, Helene; Hansen, Tue Haldor; Nielsen, Trine; Fan, Yong; Le Chatelier, Emmanuelle; Fromentin, Sébastien; Berland, Magali; Plaza Oñate, Florian; Pons, Nicolas; Galleron, Nathalie; Levenez, Florence; Markó, Lajos; Birkner, Till; Jørgensen, Torben; Forslund, Sofia K.; Vestergaard, Henrik; Hansen, Torben; Nordentoft, Merete; Mors, Ole; Benros, Michael E.; Pedersen, Oluf; Ehrlich, Stanislav D.
In: Biological Psychiatry Global Open Science, Vol. 3, No. 2, 2023, p. 283-291.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Alteration of Gut Microbiome in Patients With Schizophrenia Indicates Links Between Bacterial Tyrosine Biosynthesis and Cognitive Dysfunction
AU - Thirion, Florence
AU - Speyer, Helene
AU - Hansen, Tue Haldor
AU - Nielsen, Trine
AU - Fan, Yong
AU - Le Chatelier, Emmanuelle
AU - Fromentin, Sébastien
AU - Berland, Magali
AU - Plaza Oñate, Florian
AU - Pons, Nicolas
AU - Galleron, Nathalie
AU - Levenez, Florence
AU - Markó, Lajos
AU - Birkner, Till
AU - Jørgensen, Torben
AU - Forslund, Sofia K.
AU - Vestergaard, Henrik
AU - Hansen, Torben
AU - Nordentoft, Merete
AU - Mors, Ole
AU - Benros, Michael E.
AU - Pedersen, Oluf
AU - Ehrlich, Stanislav D.
N1 - Publisher Copyright: © 2022 The Authors
PY - 2023
Y1 - 2023
N2 - Background: Schizophrenia (SCZ) is a heterogeneous neuropsychiatric disorder for which current treatment has insufficient efficacy and severe adverse effects. The modifiable gut microbiome might be a potential target for intervention to improve neurobiological functions through the gut-microbiome-brain axis. Methods: In this case-control study, gut microbiota of 132 patients with SCZ and increased waist circumference were compared with gut microbiota of two age- and sex-matched control groups, composed of 132 healthy individuals and 132 individuals with metabolic syndrome. Shotgun sequencing was used to characterize fecal samples at the taxonomic and functional levels. Cognition of the patients with SCZ was evaluated using the Brief Assessment of Cognition instrument. Results: SCZ gut microbiota differed significantly from those of healthy control subjects and individuals with metabolic syndrome in terms of richness and global composition. SCZ gut microbiota were notably enriched in Flavonifractor plautii, Collinsella aerofaciens, Bilophila wadsworthia, and Sellimonas intestinalis, while depleted in Faecalibacterium prausnitzii, Ruminococcus lactaris, Ruminococcus bicirculans, and Veillonella rogosae. Functional potential of the gut microbiota accounted for 11% of cognition variability. In particular, the bacterial functional module for synthesizing tyrosine, a precursor for dopamine, was in SCZ cases positively associated with cognitive score (ρ = 0.34, q ≤ .1). Conclusions: Overall, this study shows that the gut microbiome of patients with SCZ differs greatly from that of healthy control subjects or individuals with metabolic syndrome. Cognitive function of patients with SCZ is associated with the potential for gut bacterial biosynthesis of tyrosine, a precursor for dopamine, suggesting that gut microbiota might be an intervention target for alleviation of cognitive dysfunction in SCZ.
AB - Background: Schizophrenia (SCZ) is a heterogeneous neuropsychiatric disorder for which current treatment has insufficient efficacy and severe adverse effects. The modifiable gut microbiome might be a potential target for intervention to improve neurobiological functions through the gut-microbiome-brain axis. Methods: In this case-control study, gut microbiota of 132 patients with SCZ and increased waist circumference were compared with gut microbiota of two age- and sex-matched control groups, composed of 132 healthy individuals and 132 individuals with metabolic syndrome. Shotgun sequencing was used to characterize fecal samples at the taxonomic and functional levels. Cognition of the patients with SCZ was evaluated using the Brief Assessment of Cognition instrument. Results: SCZ gut microbiota differed significantly from those of healthy control subjects and individuals with metabolic syndrome in terms of richness and global composition. SCZ gut microbiota were notably enriched in Flavonifractor plautii, Collinsella aerofaciens, Bilophila wadsworthia, and Sellimonas intestinalis, while depleted in Faecalibacterium prausnitzii, Ruminococcus lactaris, Ruminococcus bicirculans, and Veillonella rogosae. Functional potential of the gut microbiota accounted for 11% of cognition variability. In particular, the bacterial functional module for synthesizing tyrosine, a precursor for dopamine, was in SCZ cases positively associated with cognitive score (ρ = 0.34, q ≤ .1). Conclusions: Overall, this study shows that the gut microbiome of patients with SCZ differs greatly from that of healthy control subjects or individuals with metabolic syndrome. Cognitive function of patients with SCZ is associated with the potential for gut bacterial biosynthesis of tyrosine, a precursor for dopamine, suggesting that gut microbiota might be an intervention target for alleviation of cognitive dysfunction in SCZ.
KW - Case-control study
KW - Cognition
KW - Gut microbiome
KW - Metagenomics
KW - Schizophrenia
KW - Tyrosine biosynthesis
U2 - 10.1016/j.bpsgos.2022.01.009
DO - 10.1016/j.bpsgos.2022.01.009
M3 - Journal article
C2 - 37124355
AN - SCOPUS:85152217640
VL - 3
SP - 283
EP - 291
JO - Biological Psychiatry Global Open Science
JF - Biological Psychiatry Global Open Science
SN - 2667-1743
IS - 2
ER -
ID: 345417544